Daiichi Sankyo Company, Limited (DSKYF)
DSKYF Stock Price Chart
Explore Daiichi Sankyo Company, Limited interactive price chart. Choose custom timeframes to analyze DSKYF price movements and trends.
DSKYF Company Profile
Discover essential business fundamentals and corporate details for Daiichi Sankyo Company, Limited (DSKYF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - General
IPO Date
24 Jun 2008
Employees
18.73K
Website
https://www.daiichisankyo.comCEO
Hiroyuki Okuzawa
Description
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.
DSKYF Financial Timeline
Browse a chronological timeline of Daiichi Sankyo Company, Limited corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 23 Apr 2026
Upcoming earnings on 29 Jan 2026
Upcoming earnings on 30 Oct 2025
Revenue estimate is $3.34B.
Earnings released on 31 Jul 2025
EPS came in at $0.32 surpassing the estimated $0.24 by +34.54%, while revenue for the quarter reached $3.29B , missing expectations by -1.50%.
Dividend declared on 25 Apr 2025
A dividend of $0.27 per share was announced, adjusted to $0.27.
Dividend declared on 25 Apr 2025
A dividend of $0.27 per share was announced, adjusted to $0.27. The dividend will be paid on 1 Dec 2025.
Earnings released on 23 Apr 2025
EPS came in at $0.32 surpassing the estimated $0.14 by +127.57%, while revenue for the quarter reached $3.57B , beating expectations by +12.21%.
Earnings released on 29 Jan 2025
EPS came in at $0.21 surpassing the estimated $0.00 by +17.11K%, while revenue for the quarter reached $3.08B , beating expectations by +4.67%.
Earnings released on 31 Oct 2024
EPS came in at $0.21 surpassing the estimated $0.17 by +26.66%, while revenue for the quarter reached $3.11B , beating expectations by +4.23%.
Earnings released on 31 Jul 2024
EPS came in at $0.30 surpassing the estimated $0.13 by +135.76%, while revenue for the quarter reached $2.72B , beating expectations by +5.85%.
Earnings released on 25 Apr 2024
EPS came in at $0.12 surpassing the estimated $0.05 by +165.52%, while revenue for the quarter reached $2.82B , beating expectations by +4.99%.
Dividend declared on 25 Apr 2024
A dividend of $0.20 per share was announced, adjusted to $0.20. The dividend was paid on 24 Jun 2025.
Dividend declared on 25 Apr 2024
A dividend of $0.21 per share was announced, adjusted to $0.21. The dividend was paid on 10 Dec 2024.
Earnings released on 31 Jan 2024
EPS came in at $0.24 surpassing the estimated $0.08 by +192.77%, while revenue for the quarter reached $3.19B , beating expectations by +10.67%.
Earnings released on 31 Oct 2023
EPS came in at $0.14 falling short of the estimated $0.20 by -29.86%, while revenue for the quarter reached $2.51B , beating expectations by +3.10%.
Earnings released on 31 Jul 2023
EPS came in at $0.21 surpassing the estimated $0.14 by +49.46%, while revenue for the quarter reached $2.43B , beating expectations by +4.09%.
Earnings released on 27 Apr 2023
EPS came in at $0.09 surpassing the estimated -$0.06 by +246.63%, while revenue for the quarter reached $2.49B , beating expectations by +5.29%.
Dividend declared on 27 Apr 2023
A dividend of $0.20 per share was announced, adjusted to $0.20. The dividend was paid on 18 Jun 2024.
Dividend declared on 27 Apr 2023
A dividend of $0.13 per share was announced, adjusted to $0.11. The dividend was paid on 8 Dec 2023.
Earnings released on 31 Jan 2023
EPS came in at $0.11 falling short of the estimated $0.20 by -43.02%, while revenue for the quarter reached $2.62B , beating expectations by +0.33%.
Earnings released on 31 Oct 2022
EPS came in at $0.14 surpassing the estimated $0.12 by +21.03%, while revenue for the quarter reached $2.26B , beating expectations by +14.68%.
Earnings released on 29 Jul 2022
EPS came in at $0.07 falling short of the estimated $0.13 by -43.43%, while revenue for the quarter reached $2.06B , beating expectations by +7.25%.
Earnings released on 27 Apr 2022
EPS came in at -$0.11 falling short of the estimated -$0.10 by -6.56%, while revenue for the quarter reached $1.91B , beating expectations by +3.49%.
Dividend declared on 27 Apr 2022
A dividend of $0.11 per share was announced, adjusted to $0.11. The dividend was paid on 20 Jun 2023.
Dividend declared on 27 Apr 2022
A dividend of $0.09 per share was announced, adjusted to $0.09. The dividend was paid on 1 Dec 2022.
Earnings released on 31 Jan 2022
EPS came in at $0.14 surpassing the estimated $0.08 by +90.69%, while revenue for the quarter reached $2.44B , beating expectations by +9.50%.
Earnings released on 29 Oct 2021
EPS came in at $0.12 , while revenue for the quarter reached $2.39B , beating expectations by +1.58%.
Earnings released on 30 Jul 2021
EPS came in at $0.17 surpassing the estimated $0.09 by +76.77%, while revenue for the quarter reached $2.38B .
Earnings released on 27 Apr 2021
EPS came in at $0.00 , while revenue for the quarter reached $2.02B .
Dividend declared on 27 Apr 2021
A dividend of $0.11 per share was announced, adjusted to $0.11. The dividend was paid on 28 Jun 2022.
Dividend declared on 27 Apr 2021
A dividend of $0.12 per share was announced, adjusted to $0.12. The dividend was paid on 1 Dec 2021.
Earnings released on 29 Jan 2021
EPS came in at $0.12 falling short of the estimated $0.14 by -17.25%, while revenue for the quarter reached $2.50B , missing expectations by -99.17%.
Earnings released on 30 Oct 2020
EPS came in at $0.10 surpassing the estimated $0.04 by +135.08%, while revenue for the quarter reached $2.30B , missing expectations by -98.92%.
Stock split effective on 29 Sept 2020
Shares were split 3 : 1 , changing the number of shares outstanding and the price per share accordingly.
Dividend declared on 27 Apr 2020
A dividend of $0.12 per share was announced, adjusted to $0.12. The dividend was paid on 22 Jun 2021.
Dividend declared on 27 Apr 2020
A dividend of $0.38 per share was announced, adjusted to $0.13. The dividend was paid on 1 Dec 2020.
DSKYF Stock Performance
Access detailed DSKYF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.